Spero Therapeutics (SPRO) to Release Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. The company had revenue of $10.20 million for the quarter, compared to analyst estimates of $9.80 million. Spero Therapeutics had a return on equity of 25.67% and a net margin of 14.74%. During the same period last year, the company earned ($0.23) earnings per share. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Price Performance

Shares of SPRO traded up $0.01 during trading hours on Friday, reaching $1.32. 220,064 shares of the company's stock traded hands, compared to its average volume of 216,950. The firm has a market capitalization of $71.27 million, a price-to-earnings ratio of 3.85 and a beta of 0.63. Spero Therapeutics has a twelve month low of $1.01 and a twelve month high of $1.89. The business's fifty day simple moving average is $1.30 and its two-hundred day simple moving average is $1.37.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SPRO shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Spero Therapeutics in a report on Tuesday, August 6th. TD Cowen raised Spero Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday, August 6th. Finally, HC Wainwright lowered their target price on Spero Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a report on Monday.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.